{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:41:03Z","timestamp":1793400063811,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.intimp.2026.116783","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:17:16Z","timestamp":1777897036000},"page":"116783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Recent advances in chemokine-directed strategies to improve CAR-T cell infiltration into solid tumors"],"prefix":"10.1016","volume":"181","author":[{"given":"Jinhui","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116783_bb0005","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143729","article-title":"Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells","volume":"131","author":"Liikanen","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2026.116783_bb0010","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1007\/s00262-021-02919-2","article-title":"Complete rejection of large established breast cancer by local immunochemotherapy with T cell activation against neoantigens","volume":"70","author":"Gao","year":"2021","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.intimp.2026.116783_bb0015","first-page":"1033","article-title":"Co-expression of IL-7 and PH20 promote anti-GPC3 CAR-T tumour suppressor activity in vivo and in vitro, liver int","volume":"41","author":"Xiong","year":"2021","journal-title":"Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.intimp.2026.116783_bb0020","first-page":"4719","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor, clin. Cancer res. Off. J. Am. Assoc","volume":"17","author":"Moon","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.116783_bb0025","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/febs.14466","article-title":"A guide to chemokines and their receptors","volume":"285","author":"Hughes","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.intimp.2026.116783_bb0030","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.immuni.2012.05.008","article-title":"The chemokine superfamily revisited","volume":"36","author":"Zlotnik","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.116783_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103020","article-title":"Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors","volume":"84","author":"Hong","year":"2023","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.intimp.2026.116783_bb0040","article-title":"Harnessing the chemokine system to home CAR-T cells into solid tumors","volume":"3","author":"Foeng","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.intimp.2026.116783_bb0045","article-title":"Chemokine receptor CCR2b enhanced anti-tumor function of chimeric antigen receptor T cells targeting mesothelin in a non-small-cell lung carcinoma model","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116783_bb0050","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/s41467-022-29647-0","article-title":"Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"issue":"33","key":"10.1016\/j.intimp.2026.116783_bb0055","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"1997","author":"Craddock","year":"2010","journal-title":"J. Immunother. Hagerstown Md"},{"key":"10.1016\/j.intimp.2026.116783_bb0060","article-title":"IL-7 and CCR2b co-expression-mediated enhanced CAR-T survival and infiltration in solid Tumors","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.116783_bb0065","volume":"eLife 9","author":"Galeano Ni\u00f1o","year":"2020","journal-title":"Cytotoxic T cells swarm by homotypic chemokine signalling"},{"key":"10.1016\/j.intimp.2026.116783_bb0070","article-title":"Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells","volume":"31","author":"Chen","year":"2019","journal-title":"Adv. Mater. Deerfield Beach Fla"},{"key":"10.1016\/j.intimp.2026.116783_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106701","article-title":"Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma","volume":"189","author":"Fang","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2026.116783_bb0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41420-023-01626-4","article-title":"Recombinant oncolytic adenovirus armed with CCL5, IL-12, and IFN-\u03b3 promotes CAR-T infiltration and proliferation in vivo to eradicate local and distal tumors","volume":"9","author":"Fang","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.intimp.2026.116783_bb0085","doi-asserted-by":"crossref","DOI":"10.4161\/21505594.2014.988098","article-title":"Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors","volume":"4","author":"Nishio","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2026.116783_bb0090","article-title":"STING agonist promotes CAR T cell trafficking and persistence in breast cancer","volume":"218","author":"Xu","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2026.116783_bb0095","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-021-01168-1","article-title":"Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway, J. Hematol. Oncol","volume":"14","author":"Ji","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116783_bb0100","first-page":"1","article-title":"SATB1 prevents immune cell infiltration by regulating chromatin organization and gene expression of a chemokine gene cluster in T cells","volume":"7","author":"Wang","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.intimp.2026.116783_bb0105","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.116783_bb0110","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.scib.2020.12.027","article-title":"Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of C\u2013C motif chemokine receptor 6","volume":"66","author":"Jin","year":"2021","journal-title":"Sci. Bull."},{"key":"10.1016\/j.intimp.2026.116783_bb0115","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.3390\/ijms24065424","article-title":"Chemokine receptors CCR6 and PD1 blocking scFv E27 enhances anti-EGFR CAR-T therapeutic efficacy in a preclinical model of human non-small cell lung carcinoma","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116783_bb0120","series-title":"Validation of CCL20-Driven CAR-\u03b3\u03b4 T Secreting PD-1 Blockade with Enhanced Trafficking into Solid Tumor, iScience 28","author":"Zhang","year":"2025"},{"key":"10.1016\/j.intimp.2026.116783_bb0125","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1007\/s10565-023-09821-w","article-title":"GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy","volume":"39","author":"Lu","year":"2023","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.intimp.2026.116783_bb0130","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/2767-9764.CRC-24-0226","article-title":"Therapeutic efficacy of IL7\/CCL19-expressing CAR-T cells in intractable solid tumor models of glioblastoma and pancreatic Cancer","volume":"4","author":"Ohta","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.intimp.2026.116783_bb0135","article-title":"Development of Nectin4\/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116783_bb0140","article-title":"Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116783_bb0145","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2026.116783_bb0150","doi-asserted-by":"crossref","first-page":"10461","DOI":"10.1038\/s41598-022-14336-1","article-title":"Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo","volume":"12","author":"Zhang","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2026.116783_bb0155","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin, J. Hematol. Oncol","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116783_bb0160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-023-00625-0","article-title":"Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma","volume":"10","author":"Lei","year":"2024","journal-title":"Cell Discov."},{"key":"10.1016\/j.intimp.2026.116783_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.609421","article-title":"The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma","volume":"12","author":"Duan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116783_bb0170","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jcyt.2022.02.006","article-title":"CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma","volume":"24","author":"Schomer","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.intimp.2026.116783_bb0175","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-20-0777","article-title":"Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid Tumors without requiring preconditioned lymphodepletion, clin. Cancer res","volume":"26","author":"Luo","year":"2020","journal-title":"Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116783_bb0180","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1016\/j.ymthe.2023.06.015","article-title":"LIGHT\/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment","volume":"31","author":"Zhang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.116783_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216287","article-title":"Co-infusion of CAR T cells with aAPCs expressing chemokines and costimulatory ligands enhances the anti-tumor efficacy in mice","volume":"568","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.116783_bb0190","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1782728","article-title":"Combination of AAV-CCL19 and GPC3 CAR-T cells in the treatment of hepatocellular carcinoma","volume":"2021","author":"Meng","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.intimp.2026.116783_bb0195","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011783","article-title":"hCCL19-expressing recombinant Newcastle disease virus boosts CAR T cell infiltration and efficacy in solid tumor","volume":"13","author":"Liu","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.116783_bb0200","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi5781","article-title":"Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors","volume":"7","author":"Cadilha","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.intimp.2026.116783_bb0205","article-title":"The chemokine receptor CCR8 is a target of chimeric antigen T cells for treating T cell malignancies","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116783_bb0210","article-title":"Structure-guided engineering of CCL27 enhances natural ligand CAR T-cells against CCR10 for multiple myeloma, BioRxiv Prepr","author":"Chilakapati","year":"2025","journal-title":"Serv. Biol."},{"key":"10.1016\/j.intimp.2026.116783_bb0215","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/eji.201948457","article-title":"CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma","volume":"50","author":"Liu","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2026.116783_bb0220","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00262-024-03642-4","article-title":"Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 co-expression on functional activity","volume":"73","author":"Cao","year":"2024","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.intimp.2026.116783_bb0225","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/cancers11050674","article-title":"CAR T-cells targeting the integrin \u03b1v\u03b26 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116783_bb0230","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.116783_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115536","article-title":"Expressing IL-15\/IL-18 and CXCR2 improve infiltration and survival of EGFRvIII-targeting CAR-T cells in breast cancer","volume":"212","author":"Ruixin","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116783_bb0240","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-024-03648-y","article-title":"Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma","volume":"73","author":"Dai","year":"2024","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.intimp.2026.116783_bb0245","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41416-024-02710-x","article-title":"Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on myeloid cells within the tumor microenvironment","volume":"131","author":"Masui","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2026.116783_bb0250","article-title":"CXCL3\/TGF-\u03b2-mediated crosstalk between CAFs and tumor cells augments RCC","volume":"iScience 0","author":"Wang","year":"2024","journal-title":"Progression and Sunitinib Resistance"},{"key":"10.1016\/j.intimp.2026.116783_bb0255","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1007\/s00432-022-04509-w","article-title":"IL-2\/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K\/AKT and ERK1\/2 pathways","volume":"149","author":"Liu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116783_bb0260","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s00262-022-03193-6","article-title":"CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy","volume":"71","author":"Tian","year":"2022","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.intimp.2026.116783_bb0265","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s10238-024-01473-2","article-title":"IL-21- and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma","volume":"24","author":"Chen","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.intimp.2026.116783_bb0270","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2358590","article-title":"CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival","volume":"13","author":"Nie","year":"2024","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2026.116783_bb0275","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1089\/hum.2024.254","article-title":"Oncolytic adenovirus Armoring with CXCL9 and IL15 shows potent antitumor activity and boosts CAR-T therapy for prostate Cancer","volume":"36","author":"Fang","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.intimp.2026.116783_bb0280","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.intimp.2026.116783_bb0285","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.intimp.2026.116783_bb0290","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1395997","article-title":"Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines","volume":"7","author":"Moon","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2026.116783_bb0295","first-page":"4325","article-title":"Opening of the blood-brain barrier using low-intensity pulsed ultrasound enhances responses to immunotherapy in preclinical glioma models, clin. Cancer res. Off. J. Am. Assoc","volume":"27","author":"Sabbagh","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.116783_bb0300","article-title":"Targeting Wnt Signaling in the tumor immune microenvironment to enhancing EpCAM CAR T-cell therapy","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116783_bb0305","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1378843","article-title":"Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model","volume":"7","author":"Bocca","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2026.116783_bb0310","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/imm.13681","article-title":"FEN1 inhibitor SC13 promotes CAR-T cells infiltration into solid tumours through cGAS-STING signalling pathway","volume":"170","author":"Dong","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2026.116783_bb0315","first-page":"541","article-title":"Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase a localization, Cancer","volume":"4","author":"Newick","year":"2016","journal-title":"Immunol. Res."},{"key":"10.1016\/j.intimp.2026.116783_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117401","article-title":"Astragalus polysaccharide enhances antitumoral effects of chimeric antigen receptor- engineered (CAR) T cells by increasing CD122+CXCR3+PD-1- memory T cells","volume":"179","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2026.116783_bb0325","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0511-6","article-title":"Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC","volume":"7","author":"Gao","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.116783_bb0330","article-title":"CXCL10-induced chemotaxis of ex vivo-expanded natural killer cells combined with NKTR-255 enhances anti-tumor efficacy in osteosarcoma","volume":"0","author":"Eguchi","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.intimp.2026.116783_bb0335","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","article-title":"CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer","volume":"31","author":"Sun","year":"2023","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.intimp.2026.116783_bb0340","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1158\/1078-0432.CCR-21-0452","article-title":"Rapamycin Pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells","volume":"27","author":"Nian","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116783_bb0345","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.omto.2021.07.003","article-title":"CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells","volume":"22","author":"Li","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.intimp.2026.116783_bb0350","article-title":"CXCL13 expression promotes CAR T cell antitumor activity and potentiates response to PD-1 blockade","volume":"12","author":"Zhou","year":"2025","journal-title":"Adv. Sci. Weinh. Baden-Wurtt. Ger."},{"key":"10.1016\/j.intimp.2026.116783_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1513009","article-title":"CXCR5 engineered human and murine Tregs for targeted suppression in secondary and tertiary lymphoid organs","volume":"16","author":"Doglio","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116783_bb0360","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1186\/s12967-025-06866-9","article-title":"Enhanced homing and efficacy of HER2-CAR T cells via CXCR5\/CCR6 co-expression for HER2-positive NSCLC","volume":"23","author":"Hu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116783_bb0365","series-title":"Phase I Clinical Trial of CD19 CAR-T Cells Expressing CXCR5 Protein for the Treatment of Relapsed or Refractory B-Cell Lymphoma, Curr. Cancer Drug Targets","volume":"25","author":"W. J, J. Y, L. M, L. W, H. J, Z. M, Y. Z, J. X, X. X, C. J, L. G, D. W, Z. J, Z. Z, Z. M","year":"2025"},{"key":"10.1016\/j.intimp.2026.116783_bb0370","article-title":"Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity","volume":"0","author":"Tooley","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.intimp.2026.116783_bb0375","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.immuni.2024.04.017","article-title":"CXCL16-dependent scavenging of oxidized lipids by islet macrophages promotes differentiation of pathogenic CD8+ T cells in diabetic autoimmunity","volume":"57","author":"Srivastava","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.116783_bb0380","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41551-021-00737-6","article-title":"T cells armed with the C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours","volume":"5","author":"Lesch","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.intimp.2026.116783_bb0385","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves anti-tumor efficacy when combined with checkpoint blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.116783_bb0390","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13073-025-01498-6","article-title":"The CXCL16\/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapy","volume":"17","author":"Lu","year":"2025","journal-title":"Genome Med."},{"key":"10.1016\/j.intimp.2026.116783_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106443","article-title":"CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies","volume":"26","author":"Trinh","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.intimp.2026.116783_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112379","article-title":"Generation of CAR-TSCM: CAR-T with super clutch","volume":"136","author":"Hu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116783_bb0405","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926006296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926006296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:15:40Z","timestamp":1778591740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926006296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":81,"alternative-id":["S1567576926006296"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116783","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in chemokine-directed strategies to improve CAR-T cell infiltration into solid tumors","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116783"}}